Two PML Deaths Confirmed in Patients Taking Raptiva

Two patients who took Genentech’s psoriasis drug Raptiva for more than three years have died of progressive multifocal leukoencephalopathy (PML), a rare brain infection, and a third person who may have had the disease died of unknown causes. In addition, a nonfatal case of PML has been confirmed, Genentech says in a letter sent to healthcare providers. The four cases were reported between September 2008 and last month, FDA spokeswoman Karen Mahoney said.
Drug Industry Daily